Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma

NCT03173430 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped PI decided to close study due to slow accrual.

Conditions

Multiple Myeloma

Interventions

DRUG: Blinatumomab

Sponsor

Abramson Cancer Center at Penn Medicine